Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.
- Published In:
- Obesity (Silver Spring, Md.), 33(12), 2296-2303 (2025)
- Authors:
- Gasoyan, Hamlet, Butsch, W Scott, Casacchia, Nicholas J, Schulte, Rebecca, Criswell, Victoria, Fox, Jacqueline, Renner, Holly, Le, Phuc, Alpert, Jordan, Rothberg, Michael B
- Database ID:
- RPEP-11066
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11066APA
Gasoyan, Hamlet; Butsch, W Scott; Casacchia, Nicholas J; Schulte, Rebecca; Criswell, Victoria; Fox, Jacqueline; Renner, Holly; Le, Phuc; Alpert, Jordan; Rothberg, Michael B. (2025). Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.. Obesity (Silver Spring, Md.), 33(12), 2296-2303. https://doi.org/10.1002/oby.70058
MLA
Gasoyan, Hamlet, et al. "Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.." Obesity (Silver Spring, 2025. https://doi.org/10.1002/oby.70058
RethinkPeptides
RethinkPeptides Research Database. "Reasons for Discontinuation of Obesity Pharmacotherapy With ..." RPEP-11066. Retrieved from https://rethinkpeptides.com/research/gasoyan-2025-reasons-for-discontinuation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.